USANA Health Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Equity-Based Compensation (Tables)

12 Months Ended

Dec. 31, 2016



2017		$ 15,765
2018		13,306
2019		9,778
2020		3,642
2021+		1,978
		$ 44,469

The cost above is expected to be recognized over a weighted-average period of 3.3 years.



	Year ended

	2014	2015	2016

Expected volatility (1)	40.2%	44.0%	47.5%
Risk-free interest rate (2)	1.2%	1.3%	1.1%
Expected life (3)	3.6 yrs.	3.8 yrs.	3.7 yrs.
Expected dividend yield (4)	0.0%	0.0%	0.0%
Weighted-average exercise price (5)	$60.61	$67.71	$63.16

(1) The Company utilizes historical volatility of the trading price of its common stock.
(2) Risk-free interest rate is based on the U.S. Treasury yield curve with respect to the expected life of the award.
(3) Depending upon the terms of the award, one of two methods will be used to calculate expected life:
(i) a weighted-average that includes historical settlement data of the Company’s equity awards and a
hypothetical holding period, or (ii) the simplified method.
(4) The Company historically has not paid and currently has no plan to pay dividends.
(5) Exercise price is the closing price of the Company's common stock on the date of grant.


	Shares	Weighted-average exercise price	Weighted-average remaining contractual term	Aggregate intrinsic value*
Outstanding at January 2, 2016	4,351	$ 47.34	3.3	$ 83,475
Granted	742	63.16
Exercised	(971)	25.68
Forfeited	(731)	58.05
Expired	-	-

Outstanding at December 31, 2016	3,391	$ 54.69	3.1	$ 36,169

Exercisable at December 31, 2016	335	$ 37.69	1.6	$ 8,112